Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 5/20 | 0.64 |
| ▸ | NPC1 | O15118 | 2/20 | 0.61 |
| ▸ | RAB9A | P51151 | 2/20 | 0.61 |
| ▸ | BRAF | P15056 | 11/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | EGFR | P00533 | 9/20 | 0.57 |
| ▸ | ABL1 | P00519 | 1/20 | 0.54 |
| ▸ | CSF1R | P07333 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18775250 | 0.90 | KIT (0.78) | KITBRAFEGFRABL1CSF1R | |
| SCHEMBL18775268 | 0.90 | KIT (0.75) | KITBRAFEGFRABL1CSF1R | |
| SCHEMBL10207665 | 0.87 | KMT2A (0.58) | NPC1RAB9AALDH1A1 | |
| SCHEMBL29856195 | 0.87 | KIT (0.79) | KITBRAFABL1CSF1R | |
| SCHEMBL28439198 | 0.87 | KIT (0.79) | KITBRAFABL1CSF1R | |
| SCHEMBL12871531 | 0.87 | KIT (0.84) | KITBRAFEGFRABL1 | |
| SCHEMBL17537391 | 0.87 | KIT (0.80) | KITBRAFEGFRABL1CSF1R | |
| SCHEMBL29856172 | 0.87 | BRAF (0.66) | KITNPC1RAB9ABRAFALDH1A1 | |
| SCHEMBL21400972 | 0.86 | NPC1 (0.79) | KITNPC1RAB9AALDH1A1EGFR | |
| SCHEMBL15381992 | 0.86 | BTK (0.69) | KITNPC1RAB9AALDH1A1EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110039845-A1 | 2-AMINOQUINAZOLINE DERIVATIVE | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2011-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110039845-A1 | 2-AMINOQUINAZOLINE DERIVATIVE | H1-2, H1-3, H1-0 | KIT 3810/4885NPC1 2656/4885RAB9A 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.